Within OptiBiotix’s development pipeline SlimBiome® and the Cholesterol product have been stealing the headlines of late. This is not surprising given commercial agreements with the likes of the owners of the SlimFast brand rights in the UK, Ireland and Germany and progression from first human trials in the cholesterol product, through to pilot manufacturing studies as well as expanding the remit of this product to cover hypertension.
25 Feb 2016
The short and fatty one...
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
The short and fatty one...
OptiBiotix Health PLC (OPTI:LON) | 18.0 0 0.0% | Mkt Cap: 17.6m
- Published:
25 Feb 2016 -
Author:
Derren Nathan -
Pages:
7
Within OptiBiotix’s development pipeline SlimBiome® and the Cholesterol product have been stealing the headlines of late. This is not surprising given commercial agreements with the likes of the owners of the SlimFast brand rights in the UK, Ireland and Germany and progression from first human trials in the cholesterol product, through to pilot manufacturing studies as well as expanding the remit of this product to cover hypertension.